None listed
Conditions
Interventions
Intervention1: Bilastine: bilastine is a second-generation oral H1 antihistamine. It has emerged as a promising treatment option due to its high receptor selectivity, rapid onset of action, and lack o
Sponsors
self funded
Eligibility
Inclusion criteria
Inclusion criteria: Children between 6-18 years of age group with AR And Having a minimum reflective total nasal symptom score of 3 on at least 4 days in the previous 7 days
Exclusion criteria
Exclusion criteria: Children with known hypersensitivity to any of the study drugs Children who have received any of the following drugs in the preceding 7 days that is oral or intranasal corticosteroids oral or intranasal antihistamines or leukotriene receptor antagonists like montelukast Children with history of upper respiratory tract infection in the previous 7 days Children with any of the following disorders structural diseases of the nose or chronic sinusitis or chronic liver disease or chronic kidney disease or intellectual disability or congenital or acquired heart disease or diabetes or malignancies or primary or secondary immunodeficiency or coagulation disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measuring the change in allergic symptoms as assessed by the total reflective total nasal symptom scoreTimepoint: 2weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The individual rTNSS scores The overall scores on the MiniRQLQ Adverse effects of the study drugs Adherence to the protocol Timepoint: 2weeks | — |
Countries
India
Contacts
Public ContactDiptirekha satapathy
AIIMS Mangalagiri
Outcome results
None listed